Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences Inc.

Cassava Sciences ( ($SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cass...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	2 years
Ex-Dividend	Invalid Date	Pay Date	12/24/2012
Frequency	NA	Quarterly Est	$0.00

Date	Dec 2012	Stock Price	$17.71	TTM Div	$0.75	Yield	4.23%
Date	Dec 2010	Stock Price	$17.71	TTM Div	$2.00	Yield	11.29%

Date	12/13/2012	Amount	$0.75	Currency	USD	Frequency	I
Date	12/13/2010	Amount	$2.00	Currency	USD	Frequency	I

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SAVA	$2.87	+9.13%	1.91M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SAVA	$2.87	+9.1%	1.91M
3
4
5
6

SAVA

SAVA

Dividend Overview

Dividend Yield History

Stock Price

TTM Dividend Payout

TTM Dividend Yield

Historical Yield Data

Recent Dividend History

Get Cassava Sciences Inc. Data in Excel

Get Cassava Sciences Inc. Data in Excel